Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1998 1
2004 1
2007 2
2008 3
2009 2
2011 3
2012 2
2013 2
2014 2
2015 3
2016 3
2017 1
2018 3
2019 5
2020 6
2021 5
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Using blood calprotectin as a measure of blood neutrophils.
Åsberg A, Løfblad L, Felic A, Aune MW, Hov GG, Fagerli UM. Åsberg A, et al. Among authors: fagerli um. Scand J Clin Lab Invest. 2021 Jul;81(4):303-306. doi: 10.1080/00365513.2021.1904283. Epub 2021 Mar 31. Scand J Clin Lab Invest. 2021. PMID: 33787440
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H. Eide MB, et al. Among authors: fagerli um. Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241276 Free article. Review.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Kolstad A, et al. Among authors: fagerli um. Blood Adv. 2020 Sep 8;4(17):4091-4101. doi: 10.1182/bloodadvances.2020002583. Blood Adv. 2020. PMID: 32877524 Free PMC article. Clinical Trial.
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.
Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H. Leppä S, et al. Among authors: fagerli um. Blood Adv. 2020 May 12;4(9):1906-1915. doi: 10.1182/bloodadvances.2020001518. Blood Adv. 2020. PMID: 32380536 Free PMC article. Clinical Trial.
44 results